23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO

23andMe Holding Co. announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, May 31-June 4. 23andMe presented two posters on 23ME-00610, one each from neuroendocrine and ovarian cancer patient cohorts in its ongoing Phase 1/2a clinical trial. Key takeaways: Confirmed partial response in patient with well-differentiated pancreatic neuroendocrine cancer and qualitative clinical benefit with durable treatment duration and tumor shrinkage in patient with mesonephric adenocarcinoma. 23ME-00610 monotherapy demonstrates acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks. From archival tumor immunohistochemistry analyses, over 70% of patients had detectable tumor cell CD200, and higher expression tended to trend with clinical benefit. In addition to CD200, histology data suggest that immunosuppressed tumors may be more likely to exhibit disease control with 23ME-00610. “We continue to be pleased with the progress of 23ME-00610 as monotherapy, which continues to demonstrate therapeutic potential for inhibiting CD200R1 in cancer patients,” said Jennifer Low, M.D., Ph.D, Head of Therapeutics Development. “We are also seeing evidence of CD200 emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy. Further, we are encouraged by the continued safety and tolerability profile of 23ME-00610 which, as presented at AACR earlier this year, points to potential combination strategies for added therapeutic benefit in cancer patients.”